DE69429011D1 - Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse - Google Patents

Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse

Info

Publication number
DE69429011D1
DE69429011D1 DE69429011T DE69429011T DE69429011D1 DE 69429011 D1 DE69429011 D1 DE 69429011D1 DE 69429011 T DE69429011 T DE 69429011T DE 69429011 T DE69429011 T DE 69429011T DE 69429011 D1 DE69429011 D1 DE 69429011D1
Authority
DE
Germany
Prior art keywords
cells
pct
killer
lysis
transmitted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69429011T
Other languages
English (en)
Other versions
DE69429011T2 (de
Inventor
Edward Baral
Istvan Berczi
Eva Nagy
Corp Espoo Orion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Application granted granted Critical
Publication of DE69429011D1 publication Critical patent/DE69429011D1/de
Publication of DE69429011T2 publication Critical patent/DE69429011T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69429011T 1993-08-09 1994-08-02 Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse Expired - Fee Related DE69429011T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10351993A 1993-08-09 1993-08-09
PCT/FI1994/000333 WO1995004544A1 (en) 1993-08-09 1994-08-02 A method for sensitization of cancer cells for killer cell mediated lysis

Publications (2)

Publication Number Publication Date
DE69429011D1 true DE69429011D1 (de) 2001-12-13
DE69429011T2 DE69429011T2 (de) 2002-07-11

Family

ID=22295643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429011T Expired - Fee Related DE69429011T2 (de) 1993-08-09 1994-08-02 Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse

Country Status (16)

Country Link
US (1) US5788964A (de)
EP (1) EP0726772B1 (de)
JP (1) JPH09501174A (de)
KR (1) KR100340091B1 (de)
AT (1) ATE208207T1 (de)
AU (1) AU693459B2 (de)
CA (1) CA2168584C (de)
CZ (1) CZ285508B6 (de)
DE (1) DE69429011T2 (de)
ES (1) ES2167373T3 (de)
HU (1) HUT74425A (de)
NO (1) NO316823B1 (de)
NZ (1) NZ269149A (de)
RU (1) RU2153332C2 (de)
SK (1) SK283124B6 (de)
WO (1) WO1995004544A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
HU223344B1 (hu) * 1997-08-13 2004-06-28 Máté Hidvégi Immunstimuláns és metasztázist gátló fermentált, szárított anyag, ezt tartalmazó gyógyszerkészítmények, eljárás az előállítására és alkalmazásai
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413534B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
SK16642000A3 (sk) 1998-05-07 2002-08-06 The University Of Tennessee Research Corporation Spôsob chemoprevencie rakoviny prostaty
WO2002076499A2 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
CN1525868A (zh) * 2001-07-09 2004-09-01 埃弗顿有限公司 治疗和预防肝脏、肺脏和食道的癌症和癌症前期症状
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US6555095B1 (en) 2001-12-14 2003-04-29 Avon Products, Inc. Topical compositions and methods of application
EP1463751B1 (de) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albuminfusionsproteine
AU2004225437B2 (en) * 2003-03-28 2010-05-13 Cancer Advances, Inc. Gastrin hormone immunoassays
ES2426916T3 (es) * 2003-08-01 2013-10-25 A & G Pharmaceutical, Inc. Composiciones y procedimientos para restaurar la sensibilidad al tratamiento con antagonistas de HER2
AU2005228897B2 (en) * 2004-03-29 2009-12-10 Cancer Advances, Inc. Monoclonal antibodies to gastrin hormone
EP2567974A3 (de) * 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoklonale Antikörper gegen Progastrin
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
PL2532743T3 (pl) * 2010-02-04 2015-09-30 Toray Industries Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
CA2971216A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy
US11583576B2 (en) 2017-06-15 2023-02-21 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024833A (en) * 1988-03-10 1991-06-18 Industrial Farmaceutica Serono Spa Combined interferon/antiestrogen therapy for treatment of breast cancer
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
AU659157B2 (en) * 1991-04-30 1995-05-11 Asahi Kasei Kogyo Kabushiki Kaisha Triphenylethylene derivative and pharmaceutical preparation containing the same

Also Published As

Publication number Publication date
HUT74425A (en) 1996-12-30
CZ31696A3 (en) 1997-03-12
WO1995004544A1 (en) 1995-02-16
CA2168584C (en) 2008-10-14
US5788964A (en) 1998-08-04
NO960511L (no) 1996-02-08
CA2168584A1 (en) 1995-02-16
EP0726772B1 (de) 2001-11-07
ES2167373T3 (es) 2002-05-16
ATE208207T1 (de) 2001-11-15
JPH09501174A (ja) 1997-02-04
KR100340091B1 (ko) 2002-09-27
KR960703616A (ko) 1996-08-31
NO316823B1 (no) 2004-05-24
CZ285508B6 (cs) 1999-08-11
SK18096A3 (en) 1996-11-06
AU7263794A (en) 1995-02-28
AU693459B2 (en) 1998-07-02
NZ269149A (en) 1997-06-24
EP0726772A1 (de) 1996-08-21
DE69429011T2 (de) 2002-07-11
SK283124B6 (sk) 2003-02-04
HU9600294D0 (en) 1996-04-29
NO960511D0 (no) 1996-02-08
RU2153332C2 (ru) 2000-07-27

Similar Documents

Publication Publication Date Title
DE69429011D1 (de) Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse
ES2124424T3 (es) Azadioxacicloalquenos substituidos y su empleo como fungicidas.
CO4290417A1 (es) Nuevas benzoilguanidinas como medicamentos y su preparacion .
DE69429078T2 (de) Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
IL118158A0 (en) IL-6 activity inhibitor
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
MY116006A (en) Process for a rectificative separation of (meth) acrylic acid from a hydrophobic mixture containing crude (meth) acrylic acid
ES8501744A1 (es) Procedimiento para preparar un compuesto de 2-(fenilmetilen) cicloalquilaminas y -azetidinas.
BR8300177A (pt) Compostos,processo para sua preparacao,composicoes e processo para o combate ou inibicao de uma infestacao por microorganismos em plantas de cultura
ATE178603T1 (de) Substituierte heteroarylalkylthiopyridine zur bekämpfung von helicobacter bakterien
BR0309526B1 (pt) “Metiltiofenocarboxanilidas, processo para sua preparação e sua aplicação, composição para combater microorganismos indesejados compreendendo as referidas metiltiofenocarboxanilidas e seu processo de preparação, bem como processo para combater microorganismos indesejados ”
GR3024660T3 (en) Distillative method of recovering glycols from used antifreeze agents
DK0809627T3 (da) Hidtil ukendte borneolderivater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
NO960325L (no) Tryptaseinhibitor
ATE279521T1 (de) Regulierende nukleinsaeuresequenzen und verwendungen
ES8605472A1 (es) Procedimiento para la preparacion de derivados de 1-(n-(a- amino-a-metilacetil)-aminofenil)-2-amino-propanona
ES8506710A1 (es) Procedimiento para la obtencion de teofilin-7-acetato de ambroxol
ATE55411T1 (de) Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
RU95121818A (ru) Новые триазолопирамидоны, их получение и применение

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee